Nuveen
DGX icon

Nuveen’s Quest Diagnostics DGX Stock Holding History

Nuveen’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,000
Closed -$3K – 1144
2017
Q1 		$3K Buy
+26,000
New +$2.48M ﹤0.01% 1354

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Nuveen's DGX Position: Q2 2026 in Review

Nuveen increased its Quest Diagnostics (DGX) stake by 21% in Q2 2026, buying an estimated $19.3M and bringing the position to 563,830 shares worth $120M. The position accounts for 0.03% of the portfolio, ranked #378.

Nuveen first reported a position in DGX in Q2 2013 and has held it in 51 quarters since. The position peaked at $196M in Q2 2020. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Nuveen held 563,830 shares of Quest Diagnostics worth $120M as of Q2 2026.
  • Nuveen bought 98,405 Quest Diagnostics shares in Q2 2026, an estimated $19.3M.
  • Quest Diagnostics made up 0.03% of Nuveen's portfolio in Q2 2026, its #378 holding.
  • Nuveen first reported a position in Quest Diagnostics in Q2 2013 and has held it in 51 quarters since.
  • Nuveen's Quest Diagnostics position peaked at $196M in Q2 2020.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.